Primary Brain Tumors
7
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Safety and Imaging Study of GC1008 in Glioma
Metformin in Children With Relapsed or Refractory Solid Tumors
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid